"Around 70 new patients with testicular cancer symptoms are referred to me every year. Men with early stage cancer who receive treatment tend to have 99% five-year survival rate".
Professor Gordon Rustin specialises in gynaecological and testicular cancers, and is heavily immersed in drug developments that 'starve' targeted cells of vital blood supplies.
Prof. Rustin qualified from The Middlesex Hospital, London in 1971. He was appointed senior lecturer in medical oncology at the Charing Cross Hospital and consultant at Mount Vernon Hospital in 1984. He moved to a full-time post at Mount Vernon Hospital in 1995 and was the director of medical oncology from 1995 to 2015.
He was awarded an honorary professorship by UCL in 2001, and became the professor of cancer therapy at the Institute of Cancer Research, in 2011. Prof Rustin has published over 320 papers on the management of gynaecological cancers, germ cell tumours, the use of tumour markers, especially CA 125, and on phase I, II and III trials. His definitions using CA 125 to define response and progression of ovarian carcinoma are internationally known as the “Rustin criteria”.
In 2009, Prof Rustin gave the number 1 plenary lecture at the annual meeting of the American Society of Clinical Oncology, presenting the results of the MRC OVO5 / EORTC 55955 trials which has since been published in the Lancet. This trial showed that patients benefited from delaying chemotherapy for relapsed ovarian cancer. Prof Rustin is slowly persuading the international community to accept these counterintuitive results and change practice.
As chief investigator of the phase I trials of DMXAA, CA4P and OXI4503, he has developed a unique experience of running trials of vascular disruptive agents (VDAs). He has led the world in introducing functional imaging into determining the activity of VDAs. Until 2008, he was the chairman of the ovarian cancer sub group of the NCRI - gynaecological clinical studies group for five years.